Newron Pharmaceuticals
Publicly listed biopharmaceutical company headquartered in Bresso (Milan), Italy, focused on discovery, development and commercialization of therapies for central and peripheral nervous system disorders. The company advances small-molecule CNS drug candidates through preclinical research, global clinical development and partnering/licensing agreements.
Industries
Nr. of Employees
small (1-50)
Patents
Process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives
US-12134589-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9856207-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9603832-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9585869-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9505708-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9474739-B2
View Details
Process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives
US-12134589-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9856207-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9603832-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9585869-B2
View DetailsProcess for the production of ralfinamide salts substantially free from impurities having genotoxic effects
US-9505708-B2
View DetailsSubstituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US-9474739-B2
View DetailsProducts
Evenamide
Oral clinical-stage small molecule that selectively inhibits voltage-gated sodium channels to modulate glutamate release; developed as an add-on therapy for treatment-resistant and poorly responding schizophrenia.
Safinamide
Marketed oral MAO-B selective inhibitor indicated as adjunctive treatment for motor fluctuations in Parkinson's disease; commercial rights licensed to partners in multiple territories.
Ralfinamide
Oral small-molecule candidate from an ion-channel program targeting voltage-gated sodium channels and related activities, under development for orphan neuropathic pain indications.
Evenamide
Oral clinical-stage small molecule that selectively inhibits voltage-gated sodium channels to modulate glutamate release; developed as an add-on therapy for treatment-resistant and poorly responding schizophrenia.
Safinamide
Marketed oral MAO-B selective inhibitor indicated as adjunctive treatment for motor fluctuations in Parkinson's disease; commercial rights licensed to partners in multiple territories.
Ralfinamide
Oral small-molecule candidate from an ion-channel program targeting voltage-gated sodium channels and related activities, under development for orphan neuropathic pain indications.
Expertise Areas
- CNS drug discovery and development
- Global clinical trial management (Phases I–III and post-marketing studies)
- Ion channel pharmacology and small-molecule mechanisms
- Preclinical translational research using validated animal models
Key Technologies
- Voltage-gated sodium channel modulation
- Glutamate-modulating small-molecule therapeutics
- MAO-B selective inhibition
- Randomized double-blind placebo-controlled clinical trial design
News & Updates
Scheduled publication of the company's half-year financial report.
Announcement that screening for the international Phase III ENIGMA-TRS 1 study evaluating an add-on glutamate-modulating compound in treatment-resistant schizophrenia has completed; target enrollment of at least 600 patients and 12-week topline results expected in Q1 2027.
Company presentation and investor meetings scheduled at the H.C. Wainwright conference; CEO participation announced.
Ad hoc announcement reporting subscription of newly issued shares in support of Phase III development financing.
Financing facility of up to EUR 38 million to support development programs and expansion of the intellectual property portfolio.
Regional licensing for the clinical candidate in South Korea and initiation of Phase III program in the United States.
Scheduled publication of the company's half-year financial report.
Announcement that screening for the international Phase III ENIGMA-TRS 1 study evaluating an add-on glutamate-modulating compound in treatment-resistant schizophrenia has completed; target enrollment of at least 600 patients and 12-week topline results expected in Q1 2027.
Company presentation and investor meetings scheduled at the H.C. Wainwright conference; CEO participation announced.
Ad hoc announcement reporting subscription of newly issued shares in support of Phase III development financing.
Financing facility of up to EUR 38 million to support development programs and expansion of the intellectual property portfolio.
Regional licensing for the clinical candidate in South Korea and initiation of Phase III program in the United States.